Becton, Dickinson and Co ((BDX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The investigational study titled ‘An Investigational Study to Evaluate the Safety and Performance of the BD PosiFlush™ SafeScrub on Needleless Access Devices’ aims to assess the safety and performance of the BD PosiFlush™ SafeScrub. Conducted by Becton, Dickinson and Company, the study seeks to generate clinical data for regulatory submission in the EU, highlighting its significance in enhancing medical device safety and efficacy.
The study tests the BD PosiFlush™ SafeScrub, a device designed to improve the scrubbing process of needleless access devices (NADs) before flushing. The intervention is compared against a control group using a standard pre-filled saline syringe and alcohol pad.
This interventional study employs a randomized, parallel assignment model with no masking, focusing on basic science. Each participating site conducts both treatment and control arms, allowing for a comprehensive evaluation of the device’s performance.
The study began on October 22, 2024, with the last update submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and ensuring timely regulatory submissions.
The study’s findings could significantly impact Becton, Dickinson and Company’s stock performance by potentially enhancing their product portfolio and competitive edge in the medical device industry. Positive results may boost investor confidence, reflecting favorably on the company’s market position.
The study is currently recruiting, with further details available on the ClinicalTrials portal.